COMMUNIQUÉS West-GlobeNewswire

ITM, Helmholtz Munich and the University of Münster Announce Updated Preliminary Phase 1 Data with ITM-31 in Glioblastoma Patients
29/06/2026
Patient enrollment has been completed; all enrolled patients remain alive Data presented at the Nuclear Medicine and Neuro-Oncology (NMN) Society Annual Symposium Garching/Munich and Münster, Germany - June 29, 2026 - [...]
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
29/06/2026
COPENHAGEN, Denmark, June 29, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on June 2, 2026, under which the Company will repurchase shares for an amount up to [...]
Zelluna ASA: New share capital registered
29/06/2026
Oslo, Norway, 29 June 2026: Reference is made to the stock exchange announcement published by Zelluna ASA (the “ Company ”) on 18 June 2026 regarding a successfully placed private placement (the “ Private Placement ”) [...]
Resalis Announces Initiation of Phase 1b Clinical Study Evaluating RES-010 as Treatment to Address Unmet Needs in Obesity
29/06/2026
Torino, Italy, June 29, 2026 – Resalis Therapeutics today announced the dosing of the first participant in a Phase 1b clinical study of its lead candidate, RES-010, a novel antisense oligonucleotide targeting microRNA- [...]
Zelluna ASA activates The Royal Marsden as second clinical site for ZIMA-101, expanding clinical execution capabilities
29/06/2026
The Royal Marsden NHS Foundation Trust activated as the second clinical site in the ZIMA-101 Phase 1 trial Patient identification, pre-screening and screening activities ongoing at first activated site Company remains [...]
Zambon and Amneal Announce Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations
29/06/2026
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa Hopledo® is already [...]
Aplagon Appoints Carl Lindgren as Board Chair to Guide Later Stage Clinical and Corporate Development
29/06/2026
Veteran life sciences executive brings over 30 years of strategic and commercial leadership as Aplagon advances through Phase 2 development in multiple thrombosis-inflammatory diseases HELSINKI, June 29, 2026 (GLOBE [...]
AB Science annonce l’achèvement de l’étape 3 de la phase 1, évaluant la combinaison d’AB8939 et du vénétoclax dans le traitement de la LMA réfractaire ou en rechute
29/06/2026
COMMUNIQUÉ DE PRESSE AB SCIENCE ANNONCE L’ACHÈVEMENT DE L’ÉTAPE 3 DE LA PHASE 1, ÉVALUANT LA COMBINAISON D’AB8939 ET DU VÉNÉTOCLAX DANS LE TRAITEMENT DE LA LEUCÉMIE MYÉLOÏDE AIGUË RÉFRACTAIRE OU EN RECHUTE LA [...]
Bavarian Nordic Receives Health Canada Approval for Chikungunya Vaccine
29/06/2026
COPENHAGEN, Denmark, June 29, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced that Health Canada has approved VIMKUNYA ® (recombinant, adsorbed) for immunization to prevent disease caused by chikungunya virus [...]
Ipsen to acquire Kartos Therapeutics, expanding hemato-oncology late-stage pipeline
29/06/2026
Acquisition adds navtemadlin, a late-stage rare blood cancer asset in Phase III. This hemato-oncology program in myelofibrosis expands Ipsen’s growing Oncology portfolio Navtemadlin, an oral MDM2 inhibitor, has the [...]
AB Science reports completion of the step 3 of phase 1, evaluating the combination of AB8939 with venetoclax for the treatment of refractory or relapsed AML
29/06/2026
PRESS RELEASE AB SCIENCE REPORTS COMPLETION OF THE STEP 3 OF PHASE 1, EVALUATING THE COMBINATION OF AB8939 WITH VENETOCLAX FOR THE TREATMENT OF REFRACTORY OR RELAPSED ACUTE MYELOID LEUKEMIA THE COMBINATION OF AB8939 [...]
Ipsen acquiert Kartos Therapeutics et élargit son portefeuille d’hémato-oncologie à un stade avancé de développement
29/06/2026
Cette acquisition ajoute le navtemadlin, un candidat médicament de stade avancé contre un cancer rare du sang, actuellement en phase III de développement clinique. Ce programme d'hémato-oncologie, ciblant la [...]
Roche announces the launch of AXELIOS 1, a transformative next-generation sequencing platform
29/06/2026
AXELIOS 1 delivers a unique combination of accuracy, speed, scalability and cost efficiency, giving laboratories of all sizes the freedom to customise their workflows and explore a wider array of applications. Powered [...]
BridgeBio Announces Publication in the New England Journal of Medicine of Phase 3 PROPEL 3 Trial of Oral Infigratinib in Children Living with Achondroplasia
28/06/2026
- Phase 3 PROPEL 3 data published today in NEJM were simultaneously presented at ICCBH in a late-breaking oral presentation; presentation includes new arm span Z-score data showing a statistically significant [...]
TBoostExperts.com Announces Availability of 2026 Consumer Report on Testosterone Booster Supplements and Men’s Health Supplement Evaluation
27/06/2026
New report provides an educational framework for reviewing testosterone booster supplements, ingredient transparency, supplement labels, consumer safety considerations, and responsible product research. NEW YORK,USA, [...]
BurnTide Official Announces 2026 In Across The USA, UK, CA and AU Effective Formula Burn Tide Gummies For Weight Loss in Markets
27/06/2026
Announcing BurnTide Gummies, a natural supplement designed to complement healthy weight loss. Learn how Burn Tide fits into a balanced diet, active lifestyle, and daily wellness routine. New York City, June 27, 2026 ( [...]
Appili Therapeutics Reports Fiscal Year 2026 Financial and Operational Results
27/06/2026
LIKMEZ® (ATI-1501) commercial momentum building in U.S. market US$40 million NIAID award supporting VXV-01 advancement through Phase 1 HALIFAX, Nova Scotia, June 26, 2026 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. ( [...]
Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards and Acceptance of Plan to Regain Compliance
26/06/2026
BEDMINSTER, N.J., June 26, 2026 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (the “Company”) (NYSE American: MTNB) announced today that on June 24, 2026, it received a notice (the “Notice”) from the NYSE [...]
Nordic Naturals Ultimate Omega Featured in New Erewhon Smoothie by J Balvin
26/06/2026
Watsonville, CA, June 26, 2026 (GLOBE NEWSWIRE) -- Nordic Naturals , the #1 selling fish oil brand in the U.S.‡, today announced that its award-winning Ultimate Omega® is a featured ingredient in Erewhon's newly [...]

Pages